We are investigating experimental medications for both Non-small cell lung cancer (NSCLC) and Small cell lung cancer (SCLC)
Non-small cell lung cancer (NSCLC) accounts for about 85–90% of Lung Cancer diagnoses, while Small cell lung cancer (SCLC) is composed of 10-15% of Lung Cancer diagnoses. These two types of cancer differ in how they grow and how they spread.
Answer a few questions below to see if there are clinical trials that might be right for you.
Thank you for Considering a Clinical Trial
Below you will find clinical trials that are either currently recruiting patients (noted as Recruiting) or starting to recruit patients soon (noted as Not Yet Recruiting).
Here are some options for you to find more information:
An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)
An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers
View Trial DetailA Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)
View Trial DetailA Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)
A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)
Get updates on lung cancer clinical trials
Let us help you find a trial you might qualify for
